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Abstract 
 
Rac1b, an alternative isoform of the small GTPase RAC1, has recently be shown to be present 
in thyroid tissue and overexpressed in thyroid cancer cells, particularly in a subset of papillary thyroid 
carcinomas carrying the activating mutation BRAFV600E that are associated with an unfavorable 
outcome. On the other hand, RAC1 seems to be involved in the upregulation of NIS, the glycoprotein 
responsible for iodide uptake that allows the use of 131 I as a diagnostic and therapeutic tool, in thyroid 
cancer. However, NIS expression levels and iodine uptake in thyroid cancer cells are reduced when 
compared to normal tissue. Also, B-Raf V600E mutation has been shown to correlate with a lower 
expression of NIS. RAC1b overexpression has also been documented in breast cancer. This 
hyperactivatable variant was shown to be able to compete with and inhibit RAC1 endogenous activity in 
several signaling pathways. Breast carcinomas also express NIS but at levels too low to warrant 
treatment with 131I. Thus, in order to understand the regulatory mechanisms of NIS expression we 
aimed to evaluate the balance of RAC1/1b effect in NIS mRNA expression in follicular cell derived 
thyroid tumor samples, as well as, in a cell line derived from normal thyroid and in breast cancer cell 
lines. Understanding the necessary switch to increase NIS expression in cancer cells, would open a 
new window of opportunity to fight thyroid tumor resistance to radioiodine therapy and develop and 
possible treatment by the radiodide uptake therapy in breast cancer in a selective way.  
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Resumo 
 
A proteína Rac1b é uma variante hiperativavel da pequena GTPase RAC1, tendo sido 
recentemente demonstrada a sua sobreexpressão em carcinomas da tiróide, em particular num 
subgrupo de carcinomas papilares da tiróide positivos para a mutação BRAFV600E que apresentam uma 
progressão clínica da doença mais desfavorável. Por outro lado, RAC1 parece estar envolvida no 
estímulo da expressão de NIS, a glicoproteína responsável pela entrada de iodo nas células que 
permite a utilização de iodo 131 como diagnóstico e terapêutica em carcinomas da tiróide. No entanto, 
os níveis de expressão do NIS e entrada de iodo nas lesões malignas são reduzidos comparativamente 
ao tecido normal. Verificou-se também uma relação entre a mutação V600E em BRAF e menores níveis 
de expressão de NIS. A sobrexpressão de RAC1b foi igualmente documentada em cancro da mama. 
Esta variante hiperativavel mostrou ser capaz de competir e inibir a atividade endógena de RAC1 em 
diversas vias de sinalização. Carcinomas da mama também apresentam expressão de NIS, todavia em 
níveis demasiado baixos para viabilizar o tratamento com iodo 131. Assim de forma a compreender os 
processos regulatórios associados a expressão de NIS em tumores propusemo-nos a avaliar de que 
forma o balanço RAC1/1b poderá contribuir para a expressão de NIS em tumores da tiróide derivados 
de células foliculares, assim como em linhas celulares de tiróide normal e de carcinoma da mama. A 
compreensão de um mecanismo regulatório que permita o aumento dos níveis de NIS nas células 
cancerígenas poderá abrir uma nova janela de oportunidade para combater a resistência à terapêutica 
com iodo radioativo e desenvolver um possível tratamento através da incorporação de iodo radioativo 
em carcinoma de mama de uma forma seletiva. 
 
 
Termos Chave : RAC1b; Sodium Iodide Symporter; Tiróide; Mama; Carcinoma; 
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I – Introduction 
1. Cancer  
 
 
Cancer remains one of the most complex diseases affecting humans in our century (Grizzi et 
al., 2006). After decades of research, several biological and biochemical processes have been revealed, 
providing a start point to better understand the genesis of this malignancy and also to improve its 
treatment.   
  According to WHO (World Health Organization, 2012) cancer is characterized by an abnormal 
growth of cells and it can develop from any cell in the body and spread to other organs.  In 2012, there 
was a total of 14,1 million new cancer cases, 8.2 million cancer deaths and 32,6 million people living 
with cancer (within 5 years of diagnosis) worldwide.  
  A normal, healthy body comprises over 30 trillion cells in a complex, interdependent 
agglomerate, regulating one another’s proliferation. Indeed, normal cells reproduce only when instructed 
to do so by other surrounding cells which are being choreographed by regulatory genes. Such 
collaboration enables the maintenance of the proper size and architecture of the organism needs 
(Weinberg et al., 1996). 
Somatic mutations found in cancer genomes may be the consequence of the intrinsic slight 
infidelity of the DNA replication machinery, exogenous or endogenous mutagen exposures, enzymatic 
modification of DNA, or defective DNA repair. 
The complexity of tumor pathways have been studied over the years; a set of hallmarks have 
been proposed as a comprehensive and also simplified look at this complex disease, displaying an 
active role of the recruited normal cells in tumorigenesis rather than simple passive spectators.  
The main alterations in cell physiology proposed included sustaining proliferative signaling, 
insensitivity to growth inhibition, resistance to cell death, replicative immortality, angiogenesis and tissue 
invasion (metastasis) (Hanahan & Weinberg, 2011; Seyfried & Shelton, 2010). Additionally, two other 
important emerging hallmarks in cancer recently raised were tumor reprogramming of energy 
metabolism and the ability to evade the immune system. 
 Two mechanisms have been proposed as the main inducers of the cancer hallmarks: 
genomic/chromosomal instability and mutation, which generates random mutations at high frequency; 
tumor-promoting inflammation, allowing the recruitment of important molecules for the tumoral 
microenvironment (Hanahan and Weinberg, 2011). Malignant transformation is always conditioned by 
tumor microenvironment, where the tumor and surrounding cells act as a functional network (Serpa & 
Dias, 2011). 
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2. Thyroid Gland 
 
 The thyroid gland is the main organ of the endocrine 
system. Embryologically, the thyroid anlage begins as a 
bilobed vesicular structure at the foramen cecum of the 
tongue and descends as a component of the thyroglossal 
duct to reach its definitive position in the anterior aspect of 
the trachea below the cricoid cartilage in the neck (Figure 
I.1). It is supplied by major arteries (Camacho et al., 2011), 
has also a rich lymphatic network and is composed of two 
lobes joined by an isthmus from which, in a significant 
number of normal individuals, the “pyramidal lobe” extends 
upward. The adult gland varies in size and appearance 
according to functional activity, gender, hormonal status, and 
iodine intake (Muro-Cacho & Ku, 2000).  
  This gland is composed of two distinct hormone-producing cell types: the follicular and the 
parafollicular cells. These last parafollicular, or C cells, are dedicated to the production of the calcium-
regulating hormone calcitonin. Follicular cells comprise most of the epithelium and are responsible for 
iodine uptake and thyroid hormone synthesis;  
  The principal secretory products of the thyroid gland are L-triiodothyronine (T3) and L-thyroxide 
(T4), the only iodinecontaining hormones in vertebrates. These hormones are essential for growth, 
development and survival of vertebrates, since they regulate vital organism functions, such as body 
temperature, cardiac frequency, arterial pressure and intestinal function (Muro-Cacho & Ku, 2000). 
   Thyroglobulin (Tg), thyroperoxidase (TPO), sodium/iodide symporter (NIS), and TSH receptor 
(TSHr) are genes necessary for the synthesis of such hormones which takes place in the fully 
differentiated thyroid cell, called the thyrocite function (Nitsch et al., 2010; Fagman & Nilsson, 2011, 
Damante & Lauro, 1994. Because I- is an essential constituent of T3 and T4, both thyroid function and 
its systemic ramifications depend on an adequate supply of I to the gland. In turn, this supply, depends 
on sufficient dietary intake of I and proper function of the membrane symporter, NIS, responsible for this 
ion uptake (Doan et al., 2003). 
 
 
 
3. Thyroid Neoplasia  
 
Similar to all other organs of the body, the thyroid gland also exhibits a variety of developmental 
and acquired diseases.  
 According to the WHO (2012), thyroid malignancies are classified as carcinomas, which are by 
far the most common thyroid malignancies, sarcomas, lymphomas and even less frequent tumors 
including metastases to the thyroid (Gimm, 2000).  
Figure I.1 - Thyroid gland . 
(http://www.medical1stop.com/overac
tive-thyroid-gland-hyperthyroidism-
symptoms causes-and-treatment/) 
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 Thyroid cancer (TC) is the most common endocrine cancer, and its incidence has increased 
continuously over the last three decades worldwide. Although thyroid cancer is perceived to have a high 
survival rate, the sustained increase in thyroid carcinoma incidence worldwide has recently attracted 
considerable attention. Notwithstanding the good prognosis, a small portion of patients show recurrence 
and distant metastasis (Pak et al., 2015).  
 Despite the significant increase in its incidence, mortality for TC has not increased in equal 
measure. It appears two times more in female subjects, with a rate of the annual mortality between 0.4–
2.8 and 0.2–1.2/100.000for women and men, respectively (Edwards, 2005). 
Factors involved in the etiology of thyroid cancer include hormonal imbalance, radiation 
exposure, iodine deficient diets, or other environmental factors. Genetic alterations, at germinal or 
somatic level, also have an important role in thyroid carcinogenesis (DeLellis, 2006). 
Thyroid cancer typically occurs in thyroid nodules, which are common and can be detected by 
palpation and imaging in a large proportion of adults, particularly in the elderly individuals (Nikiforov, 
2004).   
 The thyroid gland contains two major types of epithelial cells - follicular and parafollicular or C 
cells. Therefore, Thyroid tumors may arise from these two main types of cells. Parafollicular-derived 
tumors represent only 3 to 5% of cases and are designated as medullary thyroid carcinomas (Nikiforov 
& Nikiforova, 2011).  
 Tumors arising from follicular thyroid cells may be benign forms, designated as follicular 
adenomas (FA). Based on morphological and clinical features, malignant tumors are subdivided into 
well-differentiated thyroid carcinomas (WDTC), poorly differentiated carcinoma (PDTC) and anaplastic 
carcinomas (ATC). As such, it has been suggested that follicular thyroid tumors represent a classical 
tumorigenesis model, where a unique epithelial cell may originate several types of tumors, each with 
distinctive clinico-pathological features (DeLellis, 2006).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
73%
14%
9%
4%
Thyroid Cancer Prevalence
PTC -
BRAF;RET/PTC;RAS
FTC - RAS;PAX-8-
PPAR;PIK3CA;PTEN
MTC - Familial forms
RET; Sporadic RET and
RAS
ATC - TP53; B-CATETIN;
RAS;BRAF;PIK3CA;PTEN
Figure I.2 – Thyroid Cancer Prevalence worldwide and their respectively 
most common genes mutaded (WHO, 2012).  
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The present study focused essentially in WDTC. This class of carcinoma is defined as deriving 
from the follicular epithelium and retaining basic biological characteristics of healthy thyroid tissue, 
including expression of the sodium iodide symporter (NIS), the key cellular feature for specific iodine 
uptake. In most cases WDTC share a relatively indolent natural history and good responsiveness to 
surgery and radioiodine (Muro-Cacho & Ku, 2000). This class is composed of two major tumor subtypes, 
the Papillary thyroid carcinoma (PTC) and the Follicular thyroid carcinoma (FTC).   
 
 
3.1 Papillary thyroid carcinoma (PTC) 
  
PTC is defined as a malignant epithelial tumor that shows evidence of follicular cell 
differentiation and that is characterized by a set of distinctive nuclear features. PTC is the most common 
thyroid carcinoma (about 90% of the cases), its prevalence is higher in patients between 20 and 50 year 
of age with a female to male ratio of 4–5:1. The incidence of thyroid cancer has increased from 3.6 to 
8.7 per 100,000 population between 1973 and 2000, primarily due to the increased detection of small 
(subclinical) papillary carcinomas (DeLellis, 2006). 
 PTC is mainly characterized by the distinctive nuclei, which are overlapped, larger than normal, 
present inclusions or grooves and have an empty appearance. Metastases are commonly spread to 
lymph nodes and less frequently disseminated through the blood (Muro-Cacho and Ku, 2000).  
A variety of different genetic alterations, including rearrangements and point mutations have 
been implicated in the development of PTC. Targets of these genetic events include RET, BRAF and 
RAS (point mutations) (Moura et al., 2011) (Figure I.2). In general, rearrangements have been linked 
with radiation exposure while the origin of point mutations has remained unknown.  
  Regarding to RET, BRAF, and RAS alterations it is in all commonly involved with signaling along 
with the MAPK pathway which is involved in signaling from a variety of growth factors and cell surface 
receptors. Mutations or rearrangements of these genes are present in approximately 70% of PTCs and 
they rarely overlap in the same tumor (DeLellis, 2006). 
 
 
3.2 Follicular Thyroid Carcinoma (FTC) 
 
In the respective chapter of the WHO Classification of Tumors of Endocrine Organs, follicular 
thyroid carcinoma (FTC) is defined as ‘A malignant epithelial tumor showing follicular cell differentiation 
and lacking the diagnostic nuclear features of papillary thyroid carcinoma (PTC) (WHO). 
  FTC accounts for 10% of all cases of thyroid malignancy in iodine-sufficient areas and 25%– 
40% of thyroid malignancies in areas of iodine deficiency (D’Avanzo, 2004). Conventional follicular 
carcinomas hardly ever involve regional lymph nodes and have distant metastases, most commonly to 
the lungs and bones (10–20% of cases). Follicular carcinoma has microscopic features that are similar 
to a follicular adenoma. However, a follicular carcinoma tends to be more cellular with a thick irregular 
capsule, and often with areas of necrosis and more frequent mitoses (McHenry, 2011).Follicular 
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carcinoma typically presents as a solitary “cold” nodule without cervical adenopathy or signs of 
hyperthyroidism (Muro-Cacho & Ku, 2000).  
FTCs have been known to harbor activating point mutations in RAS genes (H-RAS, K-RAS, and 
N-RAS). Somatic missense mutations in codons 12/13 and 61 of one of these three RAS genes have 
been found in 18-52% of FTC, which lead to constitutive activation of downstream signaling pathways. 
This group encode highly related 21-kDa proteins located at the inner surface of the cell membrane and 
has a key role in the transduction of signals from tyrosine kinase and G protein-coupled receptors 
(Nikiforova, 2003). A recent study highlights this hypothesis, given the use of Selumetinib, a MAPK 
pathway inhibitor, as co-adjuvant in iodide therapy, showing an increase in NIS expression and iodide 
uptake in a mouse model of thyroid cancer (Ho et al., 2013). 
 
 
 
4. RAC1: a member of the Ras superfamily of small GTPases 
 
The RAS (for rat sarcoma virus) superfamily of small guanosine triphosphatases (GTPases) 
comprises over 150 members (Ras super family) and  was first discovered as the transforming genes 
of  rat-derived Harvey and Kirsten murine sarcoma retrovirus in the early 1980s (Hankins, 1981).  
Mutations in the cellular RAS genes, which may alter the structure of RAS protein or even increase this 
gene expression levels, were thereafter demonstrated in human tumor cell lines, suggesting a role in 
growth and development, since their alterations lead to uncontrolled growth (Madaule, 1985).  
 This superfamily is divided into five major classes, accordingly with their sequence and function 
similarities: Ras, Rho, Rab, Ran and Arf.Regarding to the different classes, the Ras are generally related 
to cell proliferation, differentiation, morphology and apoptosis. TheRho family is involved in signaling 
networks that regulate actin, cell cycle progression and gene expression, influence cytoskeletal 
organization (Heasman & Ridley, 2008) and cell polarity (Park & Bi, 2007) as well as hematopoiesis. 
The Rab family, being the largest of the Ras superfamily, is involved in vesicular cargo trafficking 
between different organelles via endocytic and secretory pathways, facilitating budding from the donor 
compartment, transport to acceptors, vesicle fusion and cargo release. The Ran family, on the other 
hand, has only one member present in all eukaryotes, except for plants, being the most abundant in the 
cell and influence nuclear transport. Finally, the Arf protein family is also related to vesicle trafficking 
(Wennerberg et al., 2005).  
All of these members function as signaling nodes that are activated by different extracellular 
stimuli and regulate intracellular signaling. These signaling control gene transcription which ultimately 
determine crucial processes such as cell growth and differentiation (Rojas et al., 2012).  
The Ras superfamily are small GTP-binding proteins, with a common enzymatic activity.   
Members of this superfamily perform a general switch function that is based on active GTP-bound state, 
and an inactive GDP-bound state. The transition between the active and inactive states occurs in a 
cyclic process. In both inactive and active states, the proteins of the GTPase superfamily have a specific 
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affinity to other signaling proteins that are upstream or downstream parts of the reaction chain (Krauss 
& Haucke, 2014). 
In this study we focused on RAC1, a member of the Rho GTPases subfamily. RAC1 is one of 
the members of the Rho family of small GTPases. Rho stands for Ras homologous and like Ras proteins, 
functions as molecular switches; they are 'ON' in the GTPbound state and 'OFF' in the GDP-bound state. 
The switching between the active and inactive forms is controlled by several accessory proteins: the 
guanine nucleotide exchange factors (GEFs), GTPase-activating proteins (GAPs) and GDP-dissociation 
inhibitory factors. (Symons, 1996). RAC1 is a key intervenient in a wide variety of cellular processes, 
comprising actin remodeling, cell migration and cell cycle progression. (Ridley et al., 2003, Vega and 
Ridley, 2008). It is also related with cancer, including anchorage-independent growth, cell 
transformation, survival and invasion (Cerezo et al. 2009, Bid et al., 2013, Moshfegh et al., 2014). Under 
normal conditions RAC1 activity is controlled by the opposing activities of GEFs (which exchange GDP 
for GTP and activate RAC1), and GAP (which stimulate the conversion of bound GTP to GDP and 
inactivate RAC1) (Ridley, 2001).  
 
 
4.1 RAC1b, a hyper-activatable splicing variant of RAC1  
 
  In 1999, the Rac1 spliced isoform, Rac1b, was described by Jordan and colleagues. This 
intriguing isoform, results from an in-frame insertion of 19 amino acid residues immediately C-terminal 
to the “switch II” domain (residues 60-76) within the reading frame of the GTPase, due to its 57 additional 
nucleotides (Matos et al., 2000).These extra nucleotides result from an alternative splicing mechanism, 
carried out by the spliceosome, a massive structure and a wide number of auxiliary proteins cooperating 
to accurately recognize the splice sites and catalyze de splicing reaction (Zhou et al., 2013).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure I.3 - Alternative splicing of the small GTPase Rac1 in colorectal cells. 
Schematic representation of the human RAC1 gene with its seven coding exons, 
including the alternative exon 3b, and of the two alternative transcripts Rac1 and 
Rac1b (from Gonçalves et al., 2009). 
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The decision of which exon should be removed and which should be included, involves RNA 
sequence elements and protein regulators. Depending on different characteristics, such as position and 
function of the cis-regulatory elements, this mechanism can be divided into four classes: Exonic splicing 
enhancers (ESEs), exonic splicing silencers (ESSs), intronic splicing enhanchers (ISEs) and intronic 
splicing silencers (ISSs) (Chen et al., 2012). In the current case, Gonçalves et al. (2009), demonstrated 
that RAC1b  splicing occurs through the regulation of two antagonistic splicing factors (SR proteins), 
ASF/SF2 and SRp20, in colorectal tumor cells, which elucidate us for the need of a concert of different 
signaling pathways to provide the correct combination to regulate alternative splicing of small GTPase 
Rac1.  
 Comparably to Rac1, Rac1b presents its self predominantly in a GTP-bound active form, due to 
an accelerated GDP/GTP exchange activity, a lower rate of GDP/GTP hydrolysis and its impairment in 
interaction with RhoGDI (Matos et al., 2003).  
These features render this protein predominantly in its active state, leading to several alterations 
in cells. In fact, it has been shown that this spliced isoform is a potent inducer of cyclin D1 transcription 
and transformation of cells through NF-Kb pathway, responsible for apoptotic response and cell cycle 
progression regulation (Matos et al., 2003). In fibroblasts, the expression of RAC1b, seems to stimulate 
cell-cycle progression and survival in serum starvation conditions. (Matos et al., 2005). A role of RAC1b 
has also been discovered in MMP-3 epithelial to mesenchymal transition (EMT) in cultured cells, when 
inducing Reactive Oxygen Species (ROS) (Radisky, 2005). High levels of cellular ROS causes oxidative 
damage and induce genomic instability, stimulating carcinogenesis. In the same year, Esufali et al. 
reported that Rac1b promotes an effect on the Wnt signaling, a pathway often deregulated in colon 
cancer. Recent papers have corroborated results from about two decades ago, suggesting an oncogenic 
role for Rac1b, when upregulated in breast (Schnelzer et al., 2000), colon (Jordan, 1999) and more 
recently, lung cancer (Zhou et al., 2013) and thyroid (Silva et al., 2013).  
Another important feature of RAC1b in what concerns its tumorigenic properties, is its 
synergistic interplay with BRAFV600E. The association of BRAF V600E mutation with several human 
cancers have been reported along the years. Melanoma, sarcomas and colorectal carcinoma are among 
the group of cancers reported with this mutation. Interestingly, in 2008, a subgroup of colorectal tumors 
showed a cell survival dependency on a functional cooperation between mutant BRAF V600E and the 
overexpression of RAC1b (Matos et al., 2008). Later, Silva and co-workers, (2013,) showed that thyroid 
tissues also express RAC1b, and that RAC1b overexpression was also significantly associated with 
BRAFV600E in PTC samples. This association suggests a possible synergistic relation between these two 
proteins in thyroid malignancies similar to that previously shown in colorectal cancer (Matos et al., 2008).
  
 
 
 
 
 
 
8 
 
5. The sodium/iodide Symporter (NIS)  
 
Sodium iodide symporter gene or Solute carrier family 5 (SLC5A5) gene encodes for a 
glycoprotein responsible for the iodide uptake in follicular cells of the thyroid gland.  Several DNA 
mutations in this protein are related to hypothyroidism and thyroid dyshormonogenesis. Lack of NIS 
expression and defective iodide transport to follicular cells are associated with goiters and cancer 
treatment resistance.  
Besides the thyroid being the main organ in which NIS is expressed at high levels, several other 
tissues have been found to express NIS protein or to contain NIS mRNAs. Those include lactating 
breast, salivary gland, gastric mucosa and kidney (Petrich et al., 2002). 
 
 
5.1 NIS biochemical characterization 
 
NIS is an intrinsic plasma membrane glycoprotein with 13 
transmembrane domains, with the COOH-terminal in the intracellular 
compartment and the NH2-terminal facing the extracellular space. NIS 
is highly expressed in thyroid and lactating breast (Carrasco, 2000). 
This protein is responsible for the iodide uptake into the thyroid 
follicular cells as a fundamental first step for thyroid hormone 
biosynthesis. The human NIS (hNIS) gene is localized on chromosome 
19p12-13.2 and encodes a glycoprotein of 643 amino acids (aa) with a 
molecular mass of approximately 70-90 kDa. Though a NIS anti-body 
generated immunoreacts with mature (approximately 87-kD) 
polypeptide and a partially glycosylated (56kDa) polypeptide (Levi et 
al., 1997). This anti-COOH-terminal NIS Ab was the first available tool to experimentally probe the NIS 
secondary structure model, and it was used to confirm the model-predicted cytosolic-side location of the 
COOH terminus by immunofluorescence experiments in permeabilized thyroid rat cells (FRTL-5). 
 Six years later, Dohan et al., (2003) reported the identification of three potential Asn-
glycosylation sites in the deduced aa sequence at position 225, 485 and 479.   
  The role of NIS protein in thyroid hormone biosynthesis has been unequivocally confirmed after 
the cloning of NIS gene and the description of mutations in patients with dyshormonogenetic goiters, 
together with the functional studies of the mutated proteins (Carvalho & Ferreira, 2007). 
  Besides the thyroid being the main organ in which NIS is expressed at high levels, several other 
tissues have been found to express NIS protein or to contain NIS mRNAs. These include lactating 
breast, salivary gland, gastric mucosa and kidney (Petrich et al., 2002). 
 
 
 
 
Figure I.4 - Iodide uptake 
function of NIS (from Ahn, 2012). 
 
9 
 
5.2 NIS functional characterization 
 
 NIS transports negatively-charged solutes into the cytoplasm using an electrochemical Na+ 
gradient. This mechanism acts as the driving force for iodide uptake providing energy transfer generated 
by ouabain-sensitive Na+/K+ adenosine triphosphatase (Na+/K+-ATPase) pump (Spitzweg et al.,, 
2001). This route begins with the entrance of Iodide into lumen of the thyroid follicle, where it is organified 
in the course of thyroid hormone biosynthesis by subsequent oxidation and transfer onto tyrosol residues 
of thyroglobulin (TG) catalyzed by the thyroid peroxidase (TPO) (Carrasco, 2000; Vieja et al., 2000). 
 Iodide organification is a particular and unique characteristic of the thyroid gland, and long-term 
retention of iodide does not occur in extrathyroidal tissues expressing NIS (Ahn, 2012). In thyroid, NIS 
can be found at the basolateral membrane of the follicular cells, whereas for some tissues an apical 
localization has been described, suggesting that the NIS membrane targeting in polarized cells is cell-
type dependent (Darrouzet et al., 2014). 
 
 
5.3 NIS regulation  
 
  The NIS gene regulation occurs through different pathways according to tissue. Thyroid and 
breast are the two main tissues where NIS can be found. Several studies showed the differences in NIS 
expression and regulation in each of these tissues. In thyroid the regulation ensues mainly by TSH, 
followed by cAMP accumulation. In breast tissues, however, the cAMP levels do not influence NIS 
expression.  On the other hand, while Retinoic Acid is the principal NIS inducer in breast cancer cells, it 
was shown to decrease NIS expression in rat thyroid cells (FRTL-5). (Kogai et al., 2000; Schmutzler et 
al., 2007) 
   In thyroid cells, in the absence of TSH stimulation, NIS is not retained at the membrane, leading 
to a decrease in iodide uptake. However, there must exist alternative regulation mechanisms for the NIS 
trafficking, since several studies reported a NIS withdrawn at the membrane of non-thyroid tissues 
without TSH stimulation. Phosphorylation of NIS at serine residues in the carboxy terminus, and protein-
protein interactions are some alternative mechanism that were suggested to regulate NIS trafficking 
(Carrasco, 2000). Down-regulation or mis-targeted NIS expression is commonly found in thyroid 
carcinomas and frequently correlated with tumor dedifferentiation (Liang et al., 2005). Without a proper 
regulation, both transcriptional and post-transcriptional, this membrane protein become incapable to 
perform its key role on up taking iodide, a feature that make NIS a precious cancer therapy and diagnosis 
tool. 
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5.3.1 Transcriptional regulation of NIS 
 
The transcriptional regulation of NIS expression is complex and involves different regulatory 
regions. The activity of both thyroid-enriched and ubiquitous transcription factors is required.  The 
upstream enhancer (NUE), located in human cells between 9470 and 9046 relative to ATG (initiation 
site) and its sequence, is conserved among several species (Kogai et al., 2006).            The human 
(h)NUE can be highly stimulated by TSH and contains putative cis-elements for the Paired box gene 8, 
(Pax-8) and NK2 homebox 1 (Nkx2.1) transcription factors. These two proteins are required for thyroid 
development and differentiation (Kogai et al., 2012; Kogai et al., 2006).  
Pax-8 sites co-operate with an adjacent cAMP-responsive element to ensure complete hNUE 
activity and also leads to the repression of hNIS expression performed by Pituitary tumor-transforming 
gene-binding factor (PTTG) (a proto-oncogene implicated in thyroid cancer). Previously to this process, 
an activation of adenylyl cyclase through the Gs-protein, is needed so the cAMP levels increase and 
accumulate in thyroid cells, which leads to an indirect hNUE stimulation (Ohno et al., 1999; Taki et al, 
2002).      
  Retinoic acid (RA) is a metabolite from vitamin A, it plays a pivotal role in development, 
differentiation, and cell growth. RA role is mediated through two families of nuclear receptors, retinoic 
acid receptors (RARs) and retinoid X receptors (RXRs). All-trans RA (tRA) inhibits cell cycle progression 
and induces apoptosis in many tumor cell lines (Evans & Kaye, 1998).In clinical studies, tRA and its 
analogues showed to stimulate NIS expression in breast cancer and has an element located at position 
1375 relative to NIS ATG that mediates the activation of NIS expression in human follicular thyroid 
carcinoma cells. However, in breast cancer cells the effect is through a downstream intronic enhancer, 
which binds RAR and RXR (Tanosaki et al., 2003) Moreover, the cardiac homeobox transcription factor 
Nkx2.5, which is induced upon tRA stimulation, binds two cis-acting elements in the hNIS promoter 
located at 446 and 154 relative to ATG (Kogai, et al., 2006).   
 
 
5.3.2  Posttranscriptional regulation of NIS 
 
 Besides being finely regulated in a transcriptional level, NIS is also regulated in a pos-
translational level, especially regarding to its subcellular localization. NIS needs to be localized in the 
plasma membrane to be fully functional. This is important not only for iodide transport into the thyroid 
gland, but also for radioiodide therapy in thyroid cancer. The decrease in iodide uptake observed in most 
thyroid cancers is due to impaired NIS targeting of, or retention at, the plasma membrane.   
 A common cellular mechanism for modulating activity, subcellular activation and/or degradation 
of proteins is Phosphorylation. More recently has been reported as a posttranscriptional regulatory 
mechanism for the activity of transporters as well. Therefore, one can speculate that TSH might be also 
be involved in the NIS subcellular distribution (Ramamoorthy, et al., 1999; Glavy et al., 2000). Doahn et 
al., (2003) showed that NIS is phosphorylated in vivo and that serines are the principal residues of aa 
in which this process takes place in NIS, independently of TSH stimulation. Riedel and co-workers 
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(Riedel et al., 2001; Riedel et al., 1999) have identified five in vitro phosphorylation sites in rat NIS: 
S227, which is functionally silent; S43 and S581 which modulate transport velocity; T577 and T49 that 
modulate NIS stability. It was also proposed that hsp90 may function as a chaperone for NIS folding 
(Marsee et al., 2004).  
  More recently, a studied performed with a two hybrid yeast system revealed the interaction of 
NIS with LARG, a Rho-guanine nucleotide-exchange factor and its role in the regulation of cancer cell 
motility and invasiveness through the PDZ binding site at the C-terminal extremity of NIS and the PDZ 
domain of LARG (Huc-Brandt et al., 2011). 
In 2007, Vadysirisack et al., revealed that the MEK pathway has an effect on NIS regulation in thyroid 
cells, and a more recent study showed that MEK inhibition leads to lysomal degradation in human breast 
cancer cells (Zhang et al., 2014.)  
Under physiological conditions, besides TSH, iodide control also controls the protein expression 
level and its localization to the thyroid plasma membrane (stimulated by TSH and inhibited by an excess 
of iodide). Interestingly, it was also showed that the increased of NIS mRNA,does not necessarily 
increase iodide uptake activity, as previously exemplified by the PI3K-selective inhibitor, PI-103 (Kogai 
et al., 2008; Riedel et al., 2009) 
 
 
5.3.3 Molecular Pathways modulating NIS expression 
 
 Besides the mechanisms mentioned above which are responsible for transcriptional and 
translational modifications, there are specific molecules responsible for regulating NIS expression.  
 
 
5.3.3.1 PI3Kinase 
 
 Insulin and Insulin-like growth factor-I (IGF-I), reduces TSH-induced iodide uptake in FRTLL-rat 
thyroid cells (Saji & Kohn, 1991). However, insulin, a major regulator of Akt, was not required for the 
exogenous NIS induction in Ret/PTC1-expressing BHP2-7 cells, although the induction was mimicked 
by pharmacological inhibition of Akt. Expression of Ret/PTC stimulates the PI3K/Akt pathway in thyroid 
cells even in the absence of insulin or serum (Miyagi et al., 2004) PI3K is one of the major mediators of 
insulin/IGf signaling. Selective inhibitors of PI3K, significantly increase NIS mRNA expression in rat 
thyroid cells by stimulating its transcription. The PI3K inhibitors have a potential to increase the 
radioiodide accumulation, (Liu et al., 2007), in some differentiated thyroid cancer tissue. Kogai et al., 
(2008) also demonstrated that PI3K inhibitition significantly increases the iodide uptake in TSH-
stimulated and non-TSH stimulated FRTL-5 cells. However, the mechanisms of inhibition of iodide 
uptake by PI3K are distinct from rat thyroid cells to thyroid cancer cells. These authors also verified that 
the effect of PI3K in NIS-expressing BHP human papillary thyroid cancer cells was mimicked by an 
inhibitor of AKT, a major effector of PI3K, hence indicating a contribution of the canonical PI3K-AKT 
pathway (Kogai et al., 2008)  
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  Additional studies with human thyroid cells are therefore necessary to evaluate the impact of 
inhibitors of the PI3K pathway on NIS expression in thyroid cancer. 
An in vitro study with BHP 2–7 papillary thyroid cancer cells demonstrated stimulatory effects of sunitinib 
on NIS mRNA expression in the presence of an adenylyl cyclase activator, forskolin (Fenton et al., 
2010). Since sunitinib down-regulates the PI3K-AKT pathway (Keefe et al., 2010), it likely mimics the 
effects of PI3K inhibition on NIS expression, at least partially through PAX8 induction (Fenton et al., 
2010). 
 
 
5.3.3.2 BRAF 
 
The BRAF gene encodes the b-raf protein belonging to the raf family of serine/threonine 
kinases, responsible for regulating the MAP kinases/ERKs signaling pathway known for regulation of 
cell differentiation, proliferation, senescence and survival (Choi et al., 2014).  
The predominant mutation in the BRAF gene involves a thymidine to adenosine transversion at 
nucleotide 1,799, being the most observed mutations in BRAF, about 90% of cases (Davies et al., 2002). 
This results into an activating mutation due to substitution of valine with glutamic acid at aa 600 
(Cantwell-Doris et al., 2011). Significant progress has been made in understanding the carcinogenic 
role of BRAFV600E mutation.  
  Numerous studies have reported an association of BRAFV600E with decreased or lost expression 
of thyroid iodide-handling genes in PTC, particularly NIS (e.g. Zhang et al., 2013), while others have 
shown that introduced expression of BRAFV600E in thyroid cells could induce the silencing of various 
thyroid iodidehandling genes, most prominently the NIS gene (e.g. Liu et al., 2007). BRAF V600E 
expression could also cause misallocation of NIS in the cytoplasm in addition to its decreased 
expression in thyroid cells (Riesco-Eizaguirre et al., 2006). In in vitro cell line assays, inhibition of the 
BRAFV600E/MEK pathway or silencing of BRAFV600E expression could restore the expression of thyroid 
genes, particularly NIS in thyroid cells (Liu et al., 2007), which provided important therapeutic 
implications for targeting the BRAFV600E/MAPK pathway to restore thyroid gene expression and 
radioiodine avidity of radioiodine- refractory thyroid cancer. A recent clinical trial highlights this 
hypothesis, since the use of Selumetinib, a MAPK pathway inhibitor, as co-adjuvant in iodide therapy, 
showed an increased in NIS expression and iodide uptake in thyroid cancer cells (Ho et al., 2013). 
 
 
5.3.3.3 RAC1 
 
Besides its role in tumor associated processes, new roles of Rac1 are still emerging. In addition, 
the differential regulation of Rac1 is still not fully understood (Navarro-Lérida et al., 2015). 
In a recent study Kogai et al. (2012), using MCF-7 cells, showed a role for RAC1 in NIS 
modulation. Since the activity of the p38 MAPK cascade is regulated by tRA through Rac1, and tRA is 
the main stimulator of NIS in breast cancer cells, they used a pharmacological Rac1 inhibitor, 
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NSC23766. The p38 kinase is a MAPK, regulating cell proliferation, differentiation and migration. Four 
p38 isoforms, α, β, γ, and δ, are found in mammalian cells with variable tissue distribution and substrate 
specificity, producing differential activation of downstream effector pathways (Pramanik et al., 2003). 
tRA-induced iodide uptake was significantly decreased by the inhibitor. Induction of NIS mRNA by tRA 
was also significantly decreased by the Rac1 inhibition at every time point tested. These data indicate 
a critical role of Rac1 in the tRA-induced NIS expression in MCF-7 cells. This regulation occurs through 
a tRA up-regulation of p38 β phosphorylation through Rac1. A previous studie demonstrated that the 
p38 isoform which influences NIS expression is the p38 α in thyroid, while p38 β modulates NIS in breast 
cancer cells (Kogai et al., 2012). Therefore, although the rac1-p38 pathway stimulates NIS expression 
in both thyroid cells and breast cancer cells, (Pomerance et al., 2000), the Rac1 signal diverges into two 
pathways through the different isoforms of p38.  Over-expression of p38β, as well as of Rac1, 
significantly enhances the tRA-induced NIS expression and iodide uptake requirement of p38β for the 
NIS expression in breast cancer cells, therefore, it may provide a strategy for relatively specific induction 
of NIS in some breast cancer cells (Kogai et al., 2012). 
 
 
5.4 RAC1/RAC1b and NIS 
 
 RAC1b protein expression has been described in normal thyroid cells, as well as its 
overexpression in a number of papillary thyroid carcinomas, carrying the activating mutation BRAFV600E, 
with unfavorable outcome (Silva et al. 2013). Also, BRAF V600E has been associated with decreased or 
lost expression of NIS in PTC. 
On the other hand the GTPase Rac1 was shown to have the ability to stimulate NIS expression 
through induction of the p38 mitogenic kinase activity. More interestingly, it was shown that while 
hyperactive, the Rac1b variant has a very selective downstream signaling (Matos et al., 2003) and may 
even compete with and inhibit Rac1 endogenous activity in signaling pathways where Rac1b does not 
participate (Matos et al., 2003, Matos et al., 2006).   
One such pathway leads precisely to the activation of p38 kinase (Orlichenko et al., 2010). This 
led us to hypothesize that Rac1b overexpression in thyroid and breast tumors might be involved in the 
inhibition of NIS expression, through an RAC1 antagonistic effect. 
 
 
 
6. Iodide Therapies 
 
6.1 - Thyroid Cancer 
 
Although thyroid nodules are common, differentiated thyroid carcinomas are relatively rare. 
Managing differentiated thyroid carcinomas can be a challenge, because no prospective randomized 
trials of treatment have been performed and results from ongoing trials will not be available for many 
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years given the rareness of these tumors. Nonetheless, most thyroid cancer patients have a great 
outcome. The preferred treatment starts with the need of total thyroidectomy whenever possible. 
Therefore, the thyroid gland and the lymph nodes affect are resected thyroid hormone suppressive 
therapy, and in more advanced stages of the disease, radioactive iodine (I-131) for either remnant 
ablation or therapeutic treatment (Schulumberger, 1998; Legakis and Syrigos, 2011). 
By the end of the 19th century Baumann (1896) discovered, for the first time, the ability of thyroid 
gland to uptake and concentrate iodide; two times more than in plasma compartment. This knowledge 
was applied in thyroid diagnose and therapy only 50 years later (1942). The transport of the iodide is a 
crucial step in thyroid hormone biosynthesis and occurs through NIS. This features allows the use of 
Radioactive Iodine (I-131) as a tool to diagnosis and treatment of thyroid carcinoma. Radioiodine 
ablation of remnant thyroid following thyroidectomy is performed as an adjuvant therapy for potential 
residual tumors. Radioiodine is used to ablate any residual remnant thyroid tissues after surgical 
resection, which increases the sensitivity of subsequent tests based on serum TG measurement and 
radioiodine whole body scanning. The delivery of high radiation doses to the thyroid tissue due to the 
latter’s ability to concentrate iodine after TSH stimulation and the ability to destroy residual thyroid tissue 
cells, allows the early detection of recurrences based on serum TG (Cooper et al., 2009; Pacini et al., 
2006; Chung et al., 2010). 
Recurrence in the thyroid bed or cervical lymph nodes develops in 5% to 20% of patients with 
WDTC. Some patients develop distant metastatic disease, which decreases the 10-year survival rate of 
patients by 50% (Van Nostran, 2009; Haugen, 2010). Postoperative 131 I thyroid remnant ablation is 
performed when a tumor has the potential to recur. Several studies showed the decreased recurrence 
and disease-specific mortality when post-operative 131 I therapy is performed as a part of the initial 
treatment. However, significant controversy persists regarding which patients may benefit from 
radioactive iodine treatment and the method of radioiodine application (Chung et al., 2014). 
Nonetheless, in a study with 1004 patients with differentiated thyroid carcinoma, tumor recurrence was 
approximately 3-fold higher in patients either treated with thyroid hormone alone or given no 
postoperative medical therapy when compared with those who underwent postoperative thyroid remnant 
131 I ablation (Mazzaferri et al., 1997) 
 
 
6.2 Iodide related therapies in non-thyroid tissues 
 
 The cloning and sequencing of the human NIS gene (hNIS) has allowed investigations into the 
effect of induced NIS expression by non-thyroidal cells (Smanik et al., 1996). Several studies have 
shown that NIS expression confers the ability to concentrate iodine in a variety of cell types, such as 
lactating mammary gland, gastric mucosa, salivary and lacrimal glands, choroid plexus, skin, placenta, 
and thymus, among other tissues (Dohan et al., 2003). Focusing on breast tissue, it is known that during 
late pregnancy and lactation, active transport of iodide takes place in the mammary gland in order to 
provide an adequate supply of iodide to the newborn, through NIS. This delivery of iodide is essential 
for thyroid hormone production and proper development of the newborn’s nervous system, skeletal 
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muscle, and lungs. More interestingly, recent finding on NIS demonstrated that more than 80% of the 
human breast cancer samples studied expressed NIS, whereas none of the normal samples did (non-
lactating tissue) (Kogai et al., 2012).      NIS expression within other cell types could be used for 
diagnostic procedures and treatment of malignant diseases in other tissues such as breast cancer. 
However, NIS expression and NIS mediated radioiodine uptake (RAIU) activity are often low in breast 
cancer since the radioiodine concentration is not sufficient in such tumor cells, making the treatment 
unfeasible. Therefore, it becomes demanding to find and understand the specific regulatory 
mechanisms beyond NIS gene transcription to post-translational processing and cell trafficking. These 
investigations will eventually lead to strategies that can be used to increase functional NIS expression 
in breast cancer. 
 
 
 
7. Aim of the project 
 
 Given the context described previously, the main objective of this work is to test for a relation 
between Rac1b and NIS in thyroid and breast cancers. More specifically, given that Rac1 is involved in 
NIS regulation our aim is to understand if the overexpression of RAC1b could interfere with this process.  
 The testing will focus in the mRNA and protein expression of NIS through qRT-PCR in PTCs 
and FTC, as well as thyroid cell lines and breast cancer cell lines in order to understand the possible 
differences in RAC1/1b–NIS modulation in diverse biological systems.  
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II – Material and Methods 
 
 
1. Patient samples 
 
A total of 64 samples of primary tumors from PTC and FTC patients who underwent partial/total 
thyroidectomy in IPOLFG were analyzed. These samples were collected at surgery and immediately 
frozen and stored in liquid nitrogen. Tissue sample collection was carried out in accordance with 
protocols approved by the institutional review board and informed consent was obtained for the study, 
together with the consent for surgery. 
 
2. Cell Culture 
  
In the present study, three human cell lines were used:  Nthy-ori 3-1, MCF-7 (ATCC®-HTB-
22™and MDA-MD-231 (ATCC® CRM-HTB-26™), commercially available cell lines. These three cell 
lines are adherent and where maintained at 37ºC in a humidified 5% CO2 environment in an appropriate 
chamber (NUAIRE TM US AUTOFLOW CO2 water-jacketed incubator).   
  At least twice a week, when cultures reached confluence of about 80-95%, cells were 
subcultured.  Different culture mediums were used accordingly to cell line nature. N-thy-ori 3-1 were 
cultured in a RPMI 1640 (GIBCOTM) medium supplemented with 10% (v/v) Fetal Bovine Serum 
(FBS).The mammary gland/breast cell lines (MCF-7 and MDA-MD-231) were cultured in DMEM 
(GIBCOTM) also supplemented with 10% (v/v) FBS and 1% (v/v) glutamine. Cells were detached with 1x 
0.05% trypsin-EDTA (InvitrogenTM).  
 
 
3. Cell Transfection  
  
Transfection assay is the process of introducing nucleic acids into eukaryotic cells by nonviral 
methods.  In transient transfections, foreign DNA does not integrate into the cell genome and transfected 
gene are expressed for a limited time. In stable transfections, however, cell have integrated foreign DNA 
into their genome, and consequently, descendants of these transfected cells will also express the 
transfected gene (Kim & Eberwine, 2010). In the context of this thesis, transient transfections were used 
throughout the work.  
  Transfections were performed using the cationic lipid-based transfection reagent 
LipofectamineTM 2000 (InvitrogenTM) in 35-mm dishes (NunclonTM). Just before transfection, cells were 
fed with new fresh complete DMEM medium. Plasmid DNA (2 μg) was diluted into 125 μl OPTI-MEM 
(GIBCOTM); in an additional tube, 4 μl of transfection reagent was also diluted in 125 μl of OPTI-MEM 
and incubated 5 minutes at room temperature (RT). Diluted DNA and lipofectamine were then mixed 
gently and incubated for 20 minutes at RT to allow the formation of DNA-lipofectamine complexes. After 
18 
 
incubation, 250 µl of transfection mixture was added to each culture dish.   
  The expression vectors used in this study were kindly supplied by Doctor Peter Jordan, from 
Instituto Nacional de Saúde Dr. Ricardo Jorge: pEGFP-RAC1WT, pEGFP-RAC1L61, pEGFP-
RAC1bWT, and pEGFP-RAC1bL61. The pcDNA3.1 (+)-empty vector was used as MOCK control. 
 
 
 
 
 
 
4. RNA extraction and cDNA synthesis 
 
Total RNA was obtained from frozen tissues or from transfected cell lysates using RNeasy Mini 
Extraction Kit 74106, Qiagen), according to manufacturer’s instructions,  and 2 μg were reverse 
transcribed using random primers and SuperScript II (InvitrogenTM).  
 
 
5. Reverse Transcription (RT) Polymerase Chain Reaction (PCR) 
 
After the cDNA synthesis, PCR for NIS were performed.  Primers for specific amplification of 
NIS were NISF (5’-CCATGTATGGCGTGAACC) and NISR (5’CTTCGAAGATGTCCAGCACC), 
generating PCR product of 234 bp (Appendix supplementary Table 1).  
   PCR products were resolved by electrophoresis on a 2% (w/v) agarose gel in 1X Tris-borate-
EDTA (TBE) buffer (diluted from 10X TBE, EC-860, National diagnostics) and stained with 0.05% (v/v) 
ethidium bromide. The separated DNA was visualized under UV light and image acquired in a ChemiDoc 
XRS System (BIO-RAD). 
 
 
6. Quantitative (q) RT-PCR 
 
 The Rac1b and total Rac1 expression levels were quantified by qRT-PCR on an ABI Prism 
7900HT Sequence Detection System using specific primers and TaqMan probes from the 
Assay_on_Demand products [Hs00251654_ml (selectively amplifies Rac1b), Hs01902432_sl (amplifies 
both variants); Applied Biosystems], according to manufacturer's instructions. cDNA samples were 
diluted 20 times and 4 μl were used in each real-time PCR reaction. Amplification reactions were 
performed in triplicate for each sample. Rac1b levels were normalized to total Rac1 (Rac1b + Rac1) 
expression level. For each sample, Rac1b normalized values were then expressed relative to Rac1b 
expression level present in RNA obtained from a pool of normal thyroid tissues, used as reference 
sample. 
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The NIS and β-actin expression levels were also quantified using specific primers and 
TaqmanTM probes from Assay_on_Demand products (Hs.584804; Applied Biosystems). cDNA samples 
(both obtained from fresh tissues or transfected cell pools) were diluted 4 times and 4μL were used in 
each real-time PCR. Amplification reactions were performed in triplicate for each sample. NIS levels 
were normalized to β-actin expression level (endogenous control. For each sample, NIS normalized 
values were then expressed relative to NIS expression levels of reference sample. For NIS assessment 
in transfected cells, pCDNA3-empty transfected samples (MOCK samples) were used as reference; for 
NIS quantification in tumors, we used as reference RNA obtained from a pool of normal thyroid tissues. 
Expression values correspond to arbitrary units representing fold differences relative to the reference 
sample.  
 
 
7. Protein extracts, SDS-PAGE and Western blotting 
 
Protein extracts were obtained from cell lysates performed with RIPA (radio immunoprecipitation 
assay) Lysis buffer (appendix supplementary Table 2) and stored at -80ºC. 
The proteins were separated in a 12% (RAC1/b) sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) and the protein bands were then transferred electrophoretically to a PVDF 
membrane (Polyvinylidene fluoride; BIO-RAD). Membranes were blocked in blocking buffer (20 mM 
Tris–HCl, pH 7.6, 140 mM NaCl, 0.1% Tween-20, 5% skim milk powder) and probed with primary RAC1 
(Upstate, EMD Milipore Bioscience, Billerica, Massachusetts, United States) at 1:2000 dilution. 
Detection was carried out using secondary peroxidase-conjugated anti-mouse IgG (BioRad) at 1:5000 
dilution. The Immunoreactive bands were detected by chemiluminescence using ECL Western blotting 
substrate followed by exposure and image acquisition in a ChemiDoc XRS System (BIO-RAD).  
 
 
8. Statistical Analysis 
  
Statistical analyses weres performed with GraphPad Prism statistical software (San Diego, CA, 
USA). Values are expressed as mean ± SD.  Comparisons of rates and proportions were made using 
the unpaired two-tailed Student’s t-test.  Statistical significance was accepted at P < 0.05.  
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III - Results 
 
1. NIS expression levels in RAC1b-positive and RAC1b-negative follicular 
cell derived thyroid carcinomas.  
 
As a primary approach to test whether the RAC1 isoform, RAC1b, has a role in NIS expression 
modulation, we evaluated the NIS expression levels among samples from FTC and PTC (n=64) 
comparing tumors presenting RAC1b overexpression (n=32) to those that do not (n=32).  In order to 
make a distinction between RAC1b -overexpressing and non-overexpressing tumors, we defined a 
threshold of expression above which we considered RAC1b to be overexpressed. We set the threshold 
at the value corresponding to the mean plus two standard deviations of the Rac1b expression level in a 
set of normal thyroid tissues. Based on this threshold, 32 out of 64 PTCs (50%) were found to 
overexpress Rac1b. 
NIS expression assessment by quantitative RT-PCR indicated higher levels of NIS in samples 
negative for RAC1b expression: 0.04402 ±0.01271 comparatively to 0.01916±0.005423 in RAC1b 
positive samples ( P = 0.0384;  two-tailed Student’s t-test) (Figure III.1), allowing to suggest that tumors 
overexpressing RAC1b are associated with NIS downregulation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure III.1 - NIS expression levels in RAC1b‐positive and RAC1b‐negative PTCs and 
FTCs. NIS expression levels quantified by qRT‐ PCR, correspond to arbitrary units 
representing fold differences relative to a reference sample Values are the mean ± 
S.D.(error bars) (n= 64).  
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2. NIS expression in cell lines 
 
2.1 Effect of RAC1/1b in NIS expression in Nthy-ori 3-1 
 
 In Nthy-ori 3-1 cells, a follicular epithelial normal tissue cell line where it is supposed to exist 
substantial levels of NIS, we observed a considerably difference among NIS expression. This was found 
for cells transfected with RAC1 and RAC1b. The present data suggests that RAC1 is able to stimulate 
NIS expression, while RAC1b seems to decrease NIS levels. These results are more evident when 
comparing RAC1-L61 and RAC1b-L61 (the constitutively active variants of the GTPases RAC1/1b) 
effect on NIS. These data suggest a role of RAC1 in NIS stimulation while RAC1b seems to inhibit it 
(Figure III-2.A).  In fact, when we compare the effect on NIS expression levels among the different 
variants with the effect of RAC1 WT, we found a minor expression of NIS in RAC1b L61 transfected 
cells, dropping to half. RAC1b WT also seem to decrease NIS levels, but in a weaker way, about 30% 
(Figure III-2.B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure III.3 - RAC1/1b protein expression in Nthy-ori 3-1 transfected cells. 
Representative western blot of RAC1 and RAC1b expression in Nthy-ori 3-1 
transfected cells:  1 – RAC1b-L61-GFP; 2 – RAC1-L61-GFP; 3 – MOCK; 4 – 
RAC1b-WT-GFP; 5 – RAC1-WT-GFP; transfection monitorization. 
 
Figure III.2 - Regulation of NIS expression by RAC1 and RAC1b in N-thyroid cells A and B, effects of 
RAC1 and RAC1b (both L61 and WT) on NIS expression. A, NIS expression levels were accessed through 
quantitative RT-PCR in cells transfected with RAC1/RAC1b-WT or with the constitutively dominant mutants 
RAC1/1b-L61 and normalized to MOCK transfections. B, Comparison of the effect of the different RAC1/1b 
variants to that of RAC1-WT.Cells were transfected with: pEGFP-GFP-RAC1WT, pEGFP-GFP-RAC1L61, 
pEGFP-GFP-RAC1bWT, pEGFP-RAC1bL61 and pcDNA3.1 (+)-empty vector used as MOCK control. A 
Western blot was performed to monitor (RAC1/b) transfected levels.  
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2.2 Effect of RAC1/1b in NIS expression in MDA-MB-231 
 
Our quantitative RT-PCR showed that in MDA-MB-231 cells NIS expression is 2.5 fold higher 
in cells transfected with RAC1 L61 comparatively with RAC1b L61 transfection. Regarding to WT 
transfections, cells still showed ~1.5 times higher levels (of NIS, for RAC1 comparatively with RAC1b 
(Figure III.4.A). When comparing the effect on NIS expression to that of RAC1 -WT, both L61 and WT 
variants of RAC1b induced a notorious decrease on NIS expression: NIS levels drop to more than a 
half, in this breast cancer cell line when transfected with RAC1b comparatively with RAC1 transfections 
(Figure III.4.B).  
Figure III.3 - RAC1/1b protein expression in Nthy-ori 3-1 transfected cells. 
Representative western blot of RAC1 and RAC1b expression in Nthy-ori 3-1 
transfected cells:  1 – RAC1b-L61-GFP; 2 – RAC1-L61-GFP; 3 – MOCK; 4 – 
RAC1b-WT-GFP; 5 – RAC1-WT-GFP; transfection monitorization. 
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Figure III.4 - Regulation of NIS expression by RAC1 and RAC1b in MDA-MB-231 cells A and B, effects 
of RAC1 and RAC1b (both L61 and WT) on NIS expression. A, NIS expression levels were accessed 
through quantitative RT-PCR in cells transfected with RAC1/RAC1b-WT or with the constitutively dominant 
mutants RAC1/1b-L61 and normalized to MOCK transfections. B, Comparison of the effect of the different 
RAC1/1b variants to that of RAC1-WT. Cells were transfected with: pEGFP-GFP-RAC1WT, pEGFP-GFP-
RAC1L61, pEGFP-GFP-RAC1bWT, pEGFP-RAC1bL61 and pcDNA3.1 (+)-empty vector used as MOCK 
control. A Western blot was performed to monitor (RAC1/b) transfected levels.  
Figure III.5 - RAC1/1b protein expression in MDA-MB-231 
transfected cells. Representative western blot of RAC1 and RAC1b 
expression in MDA-MB-231 transfected cells:  1 – RAC1b-L61-GFP; 2 – 
RAC1-L61-GFP; 3 – MOCK; 4 – RAC1b-WT-GFP; 5 – RAC1-WT-GFP; 
transfection monitorization. 
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2.3 RAC1 effect on NIS expression levels in MCF-7 cells.  
 
Regarding to MCF-7 cells, we observed an increment in NIS expression levels in both RAC1-
L61 and -WT transfections. With RAC1 L61 transfection, cell showed an increase of 2.5 fold compared 
to RAC1-WT, the normalizer used (Figure III-6.A). However, comparing directly the effect of each variant 
(RAC1/1b) with RAC1-WT, the qRT-PCR results showed a subtle increase of NIS expression in RAC1b 
L61 transfect cells, comparatively with RAC1b WT or even RAC1-WT (Figure III-6.B).  
 
Figure III.6 - Regulation of NIS expression by RAC1 and RAC1b in MCF-7 cells A and B, effects of RAC1 and 
RAC1b (both L61 and WT) on NIS expression. A, NIS expression levels were accessed through quantitative RT-
PCR in cells transfected with RAC1/RAC1b-WT or with the constitutively dominant mutants RAC1/1b-L61 and 
normalized to MOCK transfections. B, Comparison of the effect of the different RAC1/1b variants to that of RAC1-
WT.Cells were transfected with: pEGFP-GFP-RAC1WT, pEGFP-GFP-RAC1L61, pEGFP-GFP-RAC1bWT, 
pEGFP-RAC1bL61 and pcDNA3.1 (+)-empty vector used as MOCK control. A Western blot was performed to 
monitor (RAC1/b) transfected levels.  
 
 
 
 
 
 
 
 
 
Figure III.7 – RAC1/1b protein expression in MCF-7 transfected MCF-7. 
Representative western blot of RAC1 and RAC1b expression in MCF-7 
transfected cells:  1 – RAC1b-L61-GFP; 2 – RAC1-L61-GFP; 3 – MOCK; 4 
– RAC1b-WT-GFP; 5 – RAC1-WT-GFP; transfection monitorization.  
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IV. Discussion 
 
 The work in this thesis highlights an opposite effect between RAC1 and RAC1b in NIS 
expression levels.  In general we found a repressor effect of RAC1b on NIS expression levels in thyroid 
tumor samples (PTC and FTC) which was corroborated through the study among three different cell 
lines, one from Thyroid follicular epithelia (Nthy-ori 3-1) and two from mammary carcinoma (MDA-MB-
231 and MCF-7) where the opposite effect between RAC1b and RAC1 was observed. 
 Matos and colleagues (2003; 2006) showed that RAC1b being a hyperactivatable isoform of 
RAC1, may develop a competitive effect on RAC1 through a downstream selective signaling. More 
recently, Kogai et al. (2012) demonstrated a positive regulation of NIS expression by RAC1 through p38 
pathway, in thyroid and breast cancer cells. Taking this into account, we suggested a relevant role for 
RAC1b in NIS inhibition, possibly through RAC1-p38 pathway, given the antagonist effect between 
RAC1b and RAC1.  
 It was recently described by our group that RAC1b is expressed in normal thyroid cells and 
seems to be overexpressed in a considerable number of papillary thyroid carcinoma positive for BRAF 
V600E mutation (Silva et al., 2013) which are associated with an unfavorable outcome and lower NIS 
expression levels. One of the main reasons for radiodide therapy resistance in thyroid cancer is the loss 
of ability to concentrate radiodide in cells, some of them precisely by the downregulation of NIS, or 
impaired subcellular localization. Hence, the importance of using a strategy for modulating NIS 
expression with therapeutic purposes was highlighted in a  clinical trial using selumetinib (a MEK1 and 
MEK2 inhibitor) as a co-ajuvant for iodide therapy , that was shown to be able to reverse refractoriness 
to radioiodine in patients with metastatic thyroid cancer (Ho et al., 2013). This approach prompt us to 
investigate the mechanisms associated with the downregulation of NIS expression in thyroid tumors, 
particularly, in the subgroup of tumors with really low levels of NIS. In this context, we aimed to assess 
the role of RAC1 in NIS stimulation, and whether its isoform, RAC1b, has a role in its inhibition.  
 In this work, the cell lines studied, were transfected with both the wild-type and constitutively 
active variants of RAC1/1b. Therefore, we could evaluate different magnitudes of the effect of the 
GTPases on NIS expression.  
 Firstly, in order to investigate if there would be differences of NIS expression between RAC1b 
overexpressing and no-overexpressing tumors, we evaluated – by a quantitative RT-PCR NIS and 
RAC1b – mRNA expression levels in a cohort of 64 follicular cell derived thyroid tumors (PTC and FTC).  
The results demonstrated that tumors with increased RAC1b levels show a decreased mRNA NIS 
expression. These results are in accordance with our initial expectations that overexpression of RAC1b 
could be somehow associated with a downregulation of NIS. Thus, the study proceeded with functional 
studies in cell lines to evaluate the effect of overexpression both variants, RAC1 and RAC1b in NIS 
expression in different biological systems. 
 In N-thy-ori 3-1 cells we demonstrated that NIS expression levels are intimately related to 
RAC1/RAC1b expression. Since N-thy-ori 3-1 is a cell line derived from normal follicular epithelia, the 
basal levels of NIS are expected to be high, making the hypothetical inhibitory effect of RAC1b easy to 
detect. In thyroid cells, several signaling pathways downstream of cAMP, such as PKA-CREB, Ref1-
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PAX8 and RAC1-p38 influence thyroid differentiated function (Kogai et al., 2006). Previous studies 
developed on FRTL-5 (thyroid from rat, cell line), also showed an important contribute of variant alfa of 
p38 for NIS expression. However, we wanted to evaluate this hypothesis in a human thyroid cell line. 
More than the inhibitory effect of RAC1b, our results indicate a stimulating effect of RAC1 in the 
expression of the sodium iodide symporter; hence corroborating previous studies (e.g. ref1; ref2). 
Transfection of RAC1-L61, showed a considerably increased on NIS expression, about two times more, 
comparative with RAC1b-L61. This effect can also be seen in WT transfected group, even though more 
modestly. With WT transfections the levels of NIS expression are about one time fold  in RAC1 
transfected comparing with RAC1b (Figure III.2(A)).   
  Few studies, related to NIS expression, have been performed in MDA-MB-231 cells, since it is 
known as a RA “resistant” cell line, showing reduced levels of RARα and RARᵦ comparatively with MCF-
7 (Liu et al., 1996). Though, we believe that this selective signaling to NIS expression modulation might 
reside as well in a cell dependent manner, making the comparatively analysis between different cell 
lines, from the same mammary carcinoma type, extremely useful.  Regarding to our quantitative RT-
PCR results, in MDA-MB-231, RAC1 L61 transfectants showed a 2,5 fold higher capacity for expressing 
NIS , comparatively with RAC1b L61 transfected cells.  (Figure III.3). In WT transfected cells, where 
RAC1/b is not constitutively active, we can still perceive the same causal effect on NIS expression. 
In a different mammary carcinoma cell line, MCF-7, we found similar results to MDA-MB-231. 
Levels of NIS expression associated with RAC1-L61 transfected cells were identical in both cell lines. 
However, when transfected with RAC1b-L61, the levels of NIS expression are lower in the MDA-MB-
231 cell line. Actually, NIS expression levels associated with RAC1b-L61 transfections in MCF-7 are 
higher than in RAC1B-WT transfectants in both cell lines. Actually, there was an increment in NIS levels 
upon RAC1b-61 transfection that was not observable in MDA-MB-231. In the latter, the levels of NIS in 
RAC1b-L61 are the lowest among all transfectants, whereas MCF-7 cells transfected with RAC1b-L61 
demonstrated a subtle increase in NIS levels. It was also observed that MDA-MB-231 cells show a 
slightly higher expression of NIS mRNA upon RAC1-WT transfection than MCF-7 in the same 
conditions.  
Given these results, we can assume that there might be a different regulatory pathway for NIS 
expression in MCF-7 cells compared with MDA-MB-231 or even N-thy-ori 3-1.  This may be related to 
differences in cellular machinery, that only become noticeable with transfection of  RAC1b constitutive 
mutant (L61), which may interfere with other regulatory pathways that contribute to NIS expression. It is 
interesting to verify that even though using a cell line that is not a standard model to NIS modulation, 
due to its lower levels of RA receptors, the effect of these GTPases on NIS can be broadly evaluated, 
demonstrating a more pronounced regulatory effect of RAC1/1b in NIS expression levels than in MCF-
7. 
The present study aimed to evaluate how the RAC1/1b manipulation might be useful for NIS 
expression modulation. Peyrottes et al., (2008) using a set of monoclonal antibodies and western blot 
analysis, demonstrated that NIS expression is in fact low in several thyroid and breast cancers. 
Understanding the necessary switch to increase NIS expression in cancer cells would open a new 
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window of opportunity to fight thyroid tumor resistance to radioiodine therapy and develop and possible 
treatment by the radiodide uptake therapy in breast cancer in a selective way.  
As mentioned before, a large number of studies have demonstrated a contributory effect of TSH 
in NIS stimulation in thyroid. Hence, some differentiated thyroid cancers (approximately 10-20%) do not 
concentrate radiodide, even after TSH stimulation (Robbins et al., 1991; Schmutzler & Koehrle 2000). 
The NIS expression regulation has been extremely difficult to characterize due to differential expression 
of several nuclear factors involved in NIS gene expression comparing normal thyroid cells and cancer 
thyroid cells. And none of the nuclear factors recognized as capable of inducing NIS has been shown 
to consistently enhance radioiodide uptake in human clinical studies (Kogai et al., 2006). Concerning 
the breast cancer cells, tRA has been shown to be the main inducer of NIS. However further studies of 
the molecular mechanisms that underlie NIS promotion are necessary in order to fully understand this 
transcriptional induction, particularly because it is a very recent finding (Kogai et al., 2012). 
Therefore, we believe that the evaluation of the balanced effect of RAC1/B in NIS expression may be a 
starting point to fully understand a new effective method for NIS expression modulation. 
 Increasing NIS mRNA does not necessarily increase iodide uptake activity, as exemplified by 
the PI3KCA-selective inhibitor, PI-103 (Kogai et al., 2008).  Another important factor influencing the 
downregulation of NIS-mediated iodide uptake is the symporter’s abundance at the cell’s plasma 
membrane. The mechanisms regulating NIS plasma membrane trafficking are still unclear. However, 
recently it has been found an important role for RAC1 in CFTR (cystic fibrosis transmembrane 
conductance regulator) chloride channel plasma membrane regulation (Moniz et al., 2013). Previously, 
Karpushev et al., (2011) have demonstrated that RAC1 signaling is involved in the regulation of the 
plasma membrane abundance of other ion channels. Accordingly, these RAC1 features made us believe 
that this GTPase may also contribute to NIS regulation on cell surface expression and whether the 
overexpression of RAC1b could also interfere with this mechanism. 
 Another important aspect, resides in the fact that in normal thyroid cells NIS is expressed on the 
basolateral membrane, while in differentiated thyroid cancer is predominantly in the cytosol (Saito et al., 
1998; Wapnir, et al., 2003). Besides, Doahn et al.(2001) did not comment whether these tumor cells 
retained their polarity. Fish and Molitoris (1994) showed that the loss of tissue polarity is a characteristic 
change seen in epithelial tumors. Thyroid cancer cells present a consequent deficit of the symporter at 
the plasma membrane (Doan et al., 2001). In thyroid normal cells, NIS is located at the basolateral 
membrane of follicular cells, whereas for some tissues an apical localization has been described (Nicola 
et al., 2009; Konati et al., 1998).Therefore, besides mRNA expression, NIS trafficking and cell correct 
polarity must be crucial for NIS functionalization. 
The present study focused merely on mRNA NIS expression levels modulation due to technical-
time limitations. Further analyses would be desirable to complement our findings. 
In sum, the results obtained in this work allow to suggest that it may be possible to regulate NIS 
mRNA levels through the balance between RAC1 and RAC1b expression. In thyroid and breast cancer 
cell lines, we found a significant positive relationship between RAC1 expression and higher levels of 
mRNA NIS, while upon RAC1b ectopic expression the levels of NIS dropped considerably. In agreement 
with a downregulating effect of RAC1b in NIS expression, our study in follicular derived thyroid tumors 
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reveled an inverse correlation between NIS levels and RAC1b overexpression. Hence, this work 
represents a first step towards the understanding of a potentially relevant regulatory mechanism of NIS 
expression and localization that might constitute a new research line for improvement and development 
of thyroid and breast cancer therapies. 
  The present data suggest that the balance between RAC1/RAC1b regulates mRNA NIS 
expression levels in thyroid and breast cancer cells. However, this is just a starting point to fully 
understand the whole regulatory mechanism that allows a selective NIS expression modulation.  
Trafficking and consequent proper subcellular localization are factors crucial for NIS functionalization.  
Due to time-technical limitations we weren’t able to proceed with further studies. 
Still, regarding mRNA expression, it might be interesting to  
induce RAC1b silencing in RAC1b-positive cell lines. With RNA interference we could switch off RAC1b 
expression in thyroid and breast cancer cell lines endogenously expressing RAC1b. Given the recent 
findings about RAC1-regulation pathway on MCF-7 cells described by Kogai et al., (2012), it would be 
as well interesting to determine if RAC1b exerts its antagonist effect on RAC1 through this same 
pathway.  
  Concerning NIS membrane trafficking, it would be also relevant to test RAC1/1b effect on NIS 
membrane localization in polarized cells. This could be performed by immunofluorescence assays in 
both thyroid and breast cancer cell lines.   
 We believe that these approaches would help us to disclosure the mechanistic links between 
RAC1/1b and NIS. This might as well contribute to develop new clinical approaches and therapeutic 
options in thyroid and breast cancers.  
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VI – Appendix  Solutions, buffer and conditions for experimental work: 
 
Supplementary Table 1 - Conditions of PCR amplification of NIS cDNA 
Stage Temperature (ºC) 
Time 
(Minutes) 
Cycles 
Initial denaturation 95 5 1 
Denaturation 95 1  
Annealing 60 1 34 
Elongation 72 1  
Final elongation 72 7 1 
Inactivation 4 ∞  
 
 
Supplementary Table 2 – Final concentrations for RIPA  buffer 
RIPA buffer (10 mL) 
20 mM Tris-HCl pH 7.5 
150 mM NaCl (106404, Merck) 
5mM KCl (104936, Merck) 
5mM MgCl2 (M-8266, Sigma) 
1% Triton X-100 (T8787, Sigma) 
ddH2O to 10 mL 
1 Complete, Mini, EDTA-free Protease Inhibitor Cocktail Tablet (11836170001, Roche) 
1 mM Orthovanadate (Na3VO4) 
1 mM Sodium fluoride (NaF) (201154, Sigma) 
 
 
Supplementary Table 3 – Solutions and final concentrations for Western Blotting 
Solutions Final Concentration 
Sample buffer 
1 U/μL Benzonase (Sigma); 5 mM MgCl2; 200 mM Tris-HCl, pH 6.8; 5% 
glycerol; 2% SDS; 100mM DTT; 0,1% (v/v) Bromophenol blue 0,1% 
SDS-PAGE 
resolving gel 
Running Gel Buffer (375 mM Tris/HCl pH 8.8); 12% Acrylamide (BioRad); 
0,1% (v/v) SDS; 0,05% (v/v) TEMED; 1% (v/v) APS 
SDS-PAGE 
stacking gel 
Stacking Gel Buffer (62,5 mM Tris/HCl pH 8.8); 4% Acrylamide (BioRad); 
0,1% (v/v) SDS; 0,05% (v/v) TEMED; 1% (v/v) APS 
Blott buffer 25 mM Tris-HCl (pH 7.6) , 192 mM glycine, 20% metanol, 0.03% SDS 
Destain 
Solution 
10% (v/v) acetic acid; 45% (v/v) Methanol 
TBST 50 mM Tris-Cl, pH 7.5, 150 mM NaCl, 0,05% (v/v) Triton X-100 (Sigma) 
TBST milk 10% (w/v) milk powder in TBST buffer 
ECL  solution 
100 mM Tris pH 8.8; 1,875 mM luminol; 225 μM cumaric acid; 0,05% (v/v) 
hydrogen peroxide 
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